Comment from Centre for Commercialization of Regenerative Medicine (CCRM)

Summary: CCRM, a business entity, supports the draft guidance but requests specific clarifications and improvements to ensure consistent, risk-based decision-making. They advocate for clearer definitions regarding NGS sensitivity, integration site analysis, and sample selection to improve regulatory efficiency and scientific rigor.